EndoVascular Technologies: Ancure Failures, Operating Room Representatives and Unfiled Reports

The EndoVascular Technologies Ancure guilty plea concerned concealed device failures and a false statement to the Food and Drug Administration, alongside a separate $49 million civil settlement over government health program payments. The manufacturer had a representative in the operating room during every implantation. Reports of failures circulated inside the company while patients, doctors and the agency went without the full account. For someone in clinical support, quality or complaint handling, this case turns on a familiar question: what happened to the information after the company received it?

The Justice Department announced the plea and civil settlement on June 12, 2003. EndoVascular Technologies, a wholly owned Guidant subsidiary based in Menlo Park, California, pleaded guilty to nine counts of shipping a misbranded medical device and one count of making false statements to the Food and Drug Administration. The civil settlement addressed claims that its conduct caused Medicare, Medicaid and Veterans Affairs to pay for adulterated and misbranded devices.

What Ancure Was and Why the Operating Room Mattered

Ancure was an endograft system used to treat abdominal aortic aneurysms. The criminal case concerned its delivery system, the equipment used during implantation. The problems described in the plea arose while doctors were trying to place the device and remove the delivery equipment.

According to the Justice Department’s account of the criminal case, Food and Drug Administration approval required a company sales representative to attend every surgery. Reports of failures were repeatedly tabulated and distributed to company officials.

A June 2011 Senate Finance Committee minority staff report described manufacturers and their representatives providing ordering, delivery, stocking, instrument support and assistance to surgeons in the operating room. In Ancure, the representative’s required presence gave the company direct knowledge of malfunctions during surgery.

For an insider, those are different pieces of evidence. The representative can describe what happened during the procedure. The complaint history can show how the event was recorded. The circulation of failure summaries can show which company officials received the information. In Ancure, the government connected all of those parts when it explained how the company knew.

The Ancure Failures the Company Did Not Report

In its guilty plea, EndoVascular admitted failing to file thousands of Medical Device Reports. The Justice Department placed the reporting period between Ancure’s approval for commercial distribution in September 1999 and its withdrawal on March 15, 2001.

During that period, the company filed 172 reports with the Food and Drug Administration. In pleading guilty, it admitted that an additional 2,628 reports had gone unfiled, against 7,632 devices sold. Each omitted report represented an incident involving a malfunction or use associated with death or serious injury.

Among the unreported incidents were 12 deaths and 57 emergency conversions to more invasive surgery. The delivery system could become stuck inside the patient. Removing it could require opening the abdomen and aorta, both to retrieve the equipment and repair the aneurysm.

The reporting duty described in the criminal announcement reached beyond incidents in which somebody had already been seriously hurt. It also covered a malfunction likely to cause or contribute to death or serious injury if it happened again. That is why a surgeon’s ability to get through a difficult procedure did not answer the company’s reporting question.

Surgeons and patients went without the full account of the failures. Medicare, Medicaid and Veterans Affairs paid for the devices, according to the civil allegations.

Breaking the Handle Became the Workaround

The Justice Department’s account of the Ancure guilty plea described representatives teaching doctors an untested way to free a stuck Ancure delivery system: break the handle and remove the catheters inside it individually. A company sales representative had helped devise the technique.

According to the Justice Department’s account, representatives offered the technique in an effort to avoid conversions to more invasive surgery, which were reportable to the Food and Drug Administration. The product’s instructions did not explain the method. Doctors had not been trained to use it, the company had not trained the representatives describing it during surgery, and EndoVascular had not sought prior FDA approval.

After a patient died in a procedure involving the technique, a group of employees concluded that the Food and Drug Administration had to be told. The company did not tell the agency. Its representatives kept explaining the workaround to surgeons.

The FDA Inspector Received a Shorter Complaint List

EndoVascular’s false-statement plea concerned the complaint list it gave a Food and Drug Administration inspector. During a July 2000 inspection of the company’s Menlo Park headquarters, the inspector focused on complaints about one type of malfunction.

The inspector asked for every complaint. The company supplied a list of 55, knowing it had received hundreds about that malfunction.

The company had the larger complaint history when it supplied the smaller one. For a complaint-handling employee, the difference lies between the original accounts and what management chose to disclose.

According to the criminal charges summarized by the Justice Department, seven employees alerted the Food and Drug Administration to fraud and concealment in October 2000. A later company-authorized investigation concluded that some of their complaints were accurate and that the business was significantly out of compliance with Food and Drug Administration rules and its own policies.

Disclosure Changed the Warnings and Instructions

EndoVascular eventually told the Food and Drug Administration about the reporting failures and its inappropriate instructions to doctors concerning the handle-breaking technique. The Justice Department dates that disclosure to March 23, 2001, after the market withdrawal.

The release says the Food and Drug Administration later permitted sales with modified warnings to customers and instructions to physicians.

The Civil Settlement Followed Government Health Program Payments

The separate civil settlement resolved claims that EndoVascular’s actions caused Medicare, Medicaid and Veterans Affairs to pay millions of dollars for adulterated and misbranded Ancure devices. That was the government-payment allegation, alongside the criminal admissions about reporting and misleading FDA.

The civil allegation followed the product into government-funded care. Following a device into a government claim therefore requires attention to the procedure and the institution that provided it, as well as the manufacturer’s product records.

For a device insider, we examine those connections with you: what the company knew about the product, what it told the people using it, and how government programs paid for the resulting care.

What Kind of Proof Is Needed to Be a Whistleblower?

For a case involving concealed device failures, the useful proof connects what happened during use, what reached the manufacturer, the company’s reporting decisions and the government payments. Ancure makes those connections tangible because the criminal account describes information at each stage inside the company.

A representative’s account can explain the stuck delivery system and the advice given to the surgeon. The product instructions and training materials provide the comparison for that advice. Complaint records and internal summaries show what the company recorded and circulated. The answer to an inspector shows what the company chose to disclose when asked directly.

We also examine records of the representative’s presence with you. The Association of periOperative Registered Nurses’ position statement reaffirmed in 2025 calls for documenting the representative’s name, company and time in the room in the intraoperative nursing record, according to the health care organization’s policy. That later guidance helps us assess who was present in a modern case.

We examine the company’s reasons for leaving a report unfiled alongside the original complaint and what it sent to the Food and Drug Administration. The agency’s reporting rules require manufacturers to retain documentation of their deliberations and decisions about whether an event was reportable.

We would compare the operating-room account with the company’s version of the event. A clinical employee may know what went wrong and what was said. A complaint-handling employee may know how that account was classified and who reviewed it. A regulatory employee may know why information was left out of a submission. Those are complementary views of the decisions the Ancure case exposed.

The reporting pattern also appears in the Justice Department’s account of Olympus Medical Systems’ 2018 guilty plea. That criminal case involved unfiled reports about infection clusters associated with duodenoscopes in Europe and the shipment of misbranded devices in the United States. An outside expert’s report identified places on the scope that could harbor bacteria and were difficult to clean. The parallel is the internal knowledge of a device problem and the failure to pass required information to FDA.

An insider does not have to see the whole business to recognize a decision they witnessed. Our work starts with that account and connects it to the product, the reporting history and the payment evidence. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Saw Where the Account Changed

If you saw a device failure disappear from a complaint summary or heard surgical advice the product instructions never mentioned, talk with our whistleblower experts. We build your strongest medical device whistleblower case with you, bring in medical device whistleblower lawyers who understand reporting concealment and government healthcare payments, and stay beside you throughout the case.